Skip to main content

Broermann Medical Innovation Award 2026: Three Pioneers of Modern Obesity and Diabetes Therapies Honored

RSS - Wszystkie kategorie
17 lis 2026, 15:06Pap
Oryginał
2 min read

Prof. Svetlana Mojsov, Prof. Dr. Richard DiMarchi, and Prof. Dr. Dr. h.c. Matthias H. Tschöp have been awarded the Broermann Medical Innovation Award 2026 for their groundbreaking research on GLP-1-based therapies against obesity and diabetes.

Hessian Minister-President Boris Rhein presented the award during a ceremony at the Hessian State Chancellery on November 17, 2026. The award, endowed with a total of one million euros, ranks among the world's highest-endowed medical honors and was established by Dr. Bernard große Broermann, founder of the Asklepios Kliniken Group.

Revolutionary Metabolic Therapies

The honored scientists made fundamental contributions to enabling modern GLP-1-based therapies against obesity and diabetes. Their work on elucidating bioactive GLP-1, signal transmission between the gut and brain, and the development of multi-hormone co-agonists (polyagonists) laid the foundation for modern drugs for weight regulation and blood sugar control.

Through their research, Prof. Dr. Richard D. DiMarchi, Prof. Dr. Svetlana Mojsov, and Prof. Dr. med. Dr. h.c. Matthias Tschöp have opened a new chapter in metabolic therapy. Their work laid the scientific foundation for what is colloquially known as the >>weight-loss injection<<.

Boris Rhein, Minister-President of Hesse

Scientific Pioneers

Prof. Svetlana Mojsov identified and chemically synthesized the active 31-amino-acid form of Glucagon-Like Peptide-1 (GLP-1) during her research at Massachusetts General Hospital and Harvard Medical School in the 1980s. Prof. Dr. Richard DiMarchi, a world-renowned peptide chemist, played a pioneering role in shaping the development of human insulin and analogues during his time at Eli Lilly and Company. Prof. Dr. Dr. h.c. Matthias H. Tschöp discovered the key role of ghrelin as the hunger hormone and developed the concept of multi-hormone co-agonists in collaboration with Richard DiMarchi.

The work of this year's laureates powerfully proves how scientific pioneering transforms into medical reality. Their discoveries surrounding GLP-1 and polyagonists have fundamentally redefined obesity and diabetes care, offering real hope to millions worldwide.

Prof. Dr. Werner Seeger, Chairman of the Jury for the Broermann Award

Global Impact

The award recipients emphasized the global significance of their research. Prof. Mojsov noted her work began over 40 years ago with a hypothesis and has benefited millions worldwide. Prof. DiMarchi highlighted how incretin-based medicines have transformed the management of excess body weight, analogous to historical treatments for excess glucose, cholesterol, and blood pressure. Prof. Tschöp expressed particular satisfaction in seeing how their discoveries are transforming the therapeutic landscape of diabetes, cardiovascular disease, fatty liver disease, and other obesity-related conditions globally.

Titia Olivia große Broermann, Shareholder of the Asklepios Kliniken Group, stated: "This year's awardees impressively demonstrate how scientific curiosity and decades of research can give rise to therapies that transform the lives of millions of people. With this award, we aim to make their outstanding achievements visible while encouraging researchers worldwide to forge new paths." The nomination phase for the Broermann Medical Innovation Award 2027 has begun, with scientists able to be nominated until March 1, 2027.

Z.ai
Article written by AI
Z.ai GLM-4.5-FlashFree
Free AI articles150 of 150
No limit after signing in with Telegram